Immunotherapy

Predicting Responses to Immunotherapy in Patients With Cancer

October 27, 2020

Natalie I. U. Vokes, MD, discusses the future of predicting how patients will respond to treatment, especially immunotherapy, based on their genomic profile.

Investigators Attempt to Uncover Basis Behind Sexual Dysmorphic and Age-Related Responses to Immunotherapy

September 17, 2020

An analysis of patient samples from The Cancer Genome Atlas indicated a possible connection between tumor responses to immunotherapy and patient baseline characteristics after investigators discovered evidence of stronger immune selection by female and younger patients in early tumorigenesis.

JAVELIN Bladder 100 Trial Impresses, Ensures Patients Have Access to Second-Line Immunotherapy at Disease Progression

July 07, 2020

Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

June 27, 2020

In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.

Combination Immunotherapy Appears Promising in Breast Cancer Subtypes

June 25, 2020

Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.

iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell Responses in Advanced Solid Tumors

June 22, 2020

“RO7198457 in combination with atezolizumab induced immune responses in the majority of patients, including preliminary data demonstrating the detection of neoantigen-specific T-cell responses within the tumor."

Survival Advantage Associated With Immune-Related Toxicity Reveals Racial Disparities in Solid Tumors

June 12, 2020

The study showed that the development of immune-related adverse events in advanced solid tumors was positively correlated with improved progression-free survival and overall survival in a retrospective analysis, which also showed that Caucasian patients developed immune-related adverse events more frequently than African American patients.